Proteomic analysis of platelet-rich and platelet-poor plasma.
And cytokines
Blood product
Growth factors
PPP
PRP
Pathway analysis
Journal
Regenerative therapy
ISSN: 2352-3204
Titre abrégé: Regen Ther
Pays: Netherlands
ID NLM: 101709085
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
18
11
2019
revised:
30
08
2020
accepted:
16
09
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Autologous blood products, such as platelet-rich plasma (PRP) are commercial products broadly used to accelerate healing of tissues after injuries. However, their content is not standardized and significantly varies in composition, which may lead to differences in clinical efficacy. Also, the underlying molecular mechanisms for therapeutic effects are not well understood. A proteomic study was performed to compare the composition of low leukocyte PRP, platelet poor plasma (PPP), and blood plasma. Pathway analysis of the proteomic data was performed to evaluate differences between plasma formulations at the molecular level. Low abundance regulatory proteins in plasma were identified and quantified as well as cellular pathways regulated by those proteins. Quantitative proteomic analysis, using multiplexed isotopically labeled tags (TMT labeling) and label-free tandem mass spectrometry, was performed on plasma, low leukocyte PRP, and PPP. Plasma formulations were derived from two blood donors (one donor per experiment). Pathway analysis of the proteomic data identified the major differences between formulations. Nearly 600 proteins were detected in three types of blood plasma formulations in two experiments. Identified proteins showed more than 50% overlap between plasma formulations. Detected proteins represented more than 100 canonical pathways, as was identified by pathway analysis. The major pathways and regulatory molecules were linked to inflammation. Three types of plasma formulations were compared in two proteomic experiments. The most represented pathways, such as Acute Phase Response, Coagulation, or System of the Complement, had many proteins in common in both experiments. In both experiments plasma sample sets had the same direction of biochemical pathway changes: up- or down-regulation. The most represented biochemical pathways are linked to inflammation.
Sections du résumé
BACKGROUND
BACKGROUND
Autologous blood products, such as platelet-rich plasma (PRP) are commercial products broadly used to accelerate healing of tissues after injuries. However, their content is not standardized and significantly varies in composition, which may lead to differences in clinical efficacy. Also, the underlying molecular mechanisms for therapeutic effects are not well understood.
PURPOSE
OBJECTIVE
A proteomic study was performed to compare the composition of low leukocyte PRP, platelet poor plasma (PPP), and blood plasma. Pathway analysis of the proteomic data was performed to evaluate differences between plasma formulations at the molecular level. Low abundance regulatory proteins in plasma were identified and quantified as well as cellular pathways regulated by those proteins.
METHODS
METHODS
Quantitative proteomic analysis, using multiplexed isotopically labeled tags (TMT labeling) and label-free tandem mass spectrometry, was performed on plasma, low leukocyte PRP, and PPP. Plasma formulations were derived from two blood donors (one donor per experiment). Pathway analysis of the proteomic data identified the major differences between formulations.
RESULTS
RESULTS
Nearly 600 proteins were detected in three types of blood plasma formulations in two experiments. Identified proteins showed more than 50% overlap between plasma formulations. Detected proteins represented more than 100 canonical pathways, as was identified by pathway analysis. The major pathways and regulatory molecules were linked to inflammation.
CONCLUSION
CONCLUSIONS
Three types of plasma formulations were compared in two proteomic experiments. The most represented pathways, such as Acute Phase Response, Coagulation, or System of the Complement, had many proteins in common in both experiments. In both experiments plasma sample sets had the same direction of biochemical pathway changes: up- or down-regulation. The most represented biochemical pathways are linked to inflammation.
Identifiants
pubmed: 33426223
doi: 10.1016/j.reth.2020.09.004
pii: S2352-3204(20)30073-0
pmc: PMC7770407
doi:
Types de publication
Journal Article
Langues
eng
Pagination
226-235Informations de copyright
© 2020 The Japanese Society for Regenerative Medicine. Production and hosting by Elsevier B.V.
Déclaration de conflit d'intérêts
Peter A. Everts, PhD, FRSM, at the time of this study served as the Chief Scientific Officer of EmCyte Corporation. He contributed to manuscript writing support and detailed discussions, and did not participate in the execution of the study. Senior author Jason L. Dragoo, MD, received several disposable Pure PRP kits and a loan centrifuge for this study from EmCyte Corporation; no financial support was given. Olga Miroshnychenko, PhD, Robert J. Chalkley, PhD, and Ryan D. Leib, PhD, declare no conflict of interest.
Références
Arthroscopy. 2012 Jul;28(7):998-1009
pubmed: 22738751
Am J Sports Med. 2017 Mar;45(4):945-953
pubmed: 28027451
Nat Rev Immunol. 2015 Feb;15(2):104-16
pubmed: 25614320
Am J Sports Med. 2011 Oct;39(10):2135-40
pubmed: 21846925
Sports Med Arthrosc Rev. 2013 Dec;21(4):186-90
pubmed: 24212365
Nat Commun. 2017 Sep 15;8(1):552
pubmed: 28916756
J Immunol. 2013 Apr 15;190(8):3831-8
pubmed: 23564577
Nat Methods. 2007 Mar;4(3):207-14
pubmed: 17327847
Protein Pept Lett. 2002 Jun;9(3):211-23
pubmed: 12144517
Mol Cell Proteomics. 2002 Nov;1(11):845-67
pubmed: 12488461
Clin Oral Implants Res. 2006 Apr;17(2):212-9
pubmed: 16584418
Surgeon. 2012 Jun;10(3):148-50
pubmed: 22525416
Am J Sports Med. 2011 Jun;39(6):1200-8
pubmed: 21422467
Am J Sports Med. 2014 Feb;42(2):463-71
pubmed: 23825183
J Bone Joint Surg Am. 2012 Dec 5;94(23):e1721-7
pubmed: 23224392
Biomed Res Int. 2014;2014:630870
pubmed: 25147809
J Clin Invest. 2006 Mar;116(3):607-14
pubmed: 16511593
Genome Biol. 2003;4(5):P3
pubmed: 12734009
Am J Sports Med. 2016 Aug;44(8):1931-40
pubmed: 27400714
Sports Med Arthrosc Rev. 2013 Dec;21(4):180-5
pubmed: 24212364
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
Mol Cell Proteomics. 2004 Apr;3(4):311-26
pubmed: 14718574
PLoS One. 2014 Feb 28;9(2):e90538
pubmed: 24587389
Thromb J. 2015 May 06;13:17
pubmed: 25949215
J Mol Signal. 2011 Oct 05;6:12
pubmed: 21970630
J Zhejiang Univ Sci B. 2005 Nov;6(11):1045-56
pubmed: 16252337
Am J Sports Med. 2019 Apr;47(5):1130-1137
pubmed: 30840831
PLoS One. 2013 Jun 07;8(6):e64923
pubmed: 23762264
Am J Sports Med. 2014 May;42(5):1204-10
pubmed: 24634448
Am J Sports Med. 2019 Nov;47(13):3238-3246
pubmed: 31603721
Bone Joint Res. 2016 Mar;5(3):92-4
pubmed: 26985010
Sports Med Arthrosc Rev. 2013 Dec;21(4):225-30
pubmed: 24212371
Am J Sports Med. 2014 May;42(5):1211-8
pubmed: 24627579
Br J Sports Med. 2004 Jun;38(3):372-80
pubmed: 15155453
Int J Mol Sci. 2019 Feb 05;20(3):
pubmed: 30764506
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 May 15;1021:57-68
pubmed: 26868616